Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sudarshan Pharma Industries's Revenue for the
three
months ended in Jun. 2026 was ₹1,744 Mil. Sudarshan Pharma Industries's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹2,333 Mil.
Hence, Sudarshan Pharma Industries's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.75.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sudarshan Pharma Industries Receivables Turnover Related Terms
Sudarshan Pharma Industries Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543828 vs DOW: Receivables Turnover Comparison
For the Chemicals subindustry, Sudarshan Pharma Industries's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudarshan Pharma Industries Receivables Turnover vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Sudarshan Pharma Industries's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sudarshan Pharma Industries's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudarshan Pharma Industries (BOM:543828) has a Receivables Turnover of 0.75 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sudarshan Pharma Industries and its competitors. According to the industry distribution chart, Sudarshan Pharma Industries ranks #1257 out of 1588 companies in the Chemicals industry, placing it in the top 79.2%.
Is Sudarshan Pharma Industries' Receivables Turnover too high?
Sudarshan Pharma Industries' current Receivables Turnover is 0.75. The Chemicals industry median Receivables Turnover is 5.77. Sudarshan Pharma Industries' value of 0.75 is 87% below this industry median. Based on the distribution chart, Sudarshan Pharma Industries ranks #1257 out of 1588 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Sudarshan Pharma Industries has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sudarshan Pharma Industries' Receivables Turnover compare to DOW?
According to the Chemicals industry distribution chart, Sudarshan Pharma Industries ranks #1257 out of 1588 companies for Receivables Turnover. This places Sudarshan Pharma Industries in the lower half of its industry. The industry median Receivables Turnover is 5.77. Sudarshan Pharma Industries' value of 0.75 is 87% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Chemicals company?
The median Receivables Turnover among Chemicals companies is 5.77, based on 1,588 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudarshan Pharma Industries's current Receivables Turnover of 0.75 is 87% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sudarshan Pharma Industries and its competitors. For the Chemicals industry, the median Receivables Turnover is 5.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudarshan Pharma Industries's current Receivables Turnover is 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudarshan Pharma Industries stock overvalued right now?
Based on GuruFocus' analysis, Sudarshan Pharma Industries (BOM:543828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.95, compared to a current price of ₹39.45 — trading 467.6% above its estimated fair value. The current Receivables Turnover is 0.75 and 87% below the Chemicals industry median of 5.77. Sudarshan Pharma Industries' overall GF Score™ is 74/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sudarshan Pharma Industries (BOM:543828), the current Receivables Turnover is 0.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sudarshan Pharma Industries (BOM:543828) Overvalued in 2026?
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued.
The current stock price of ₹39.45 is trading 467.6% above its estimated GF Value™ of ₹6.95.
GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
Receivables Turnover: 0.75
GF Value™: ₹6.95 vs. price of ₹39.45 (467.6% above fair value)
Industry Position: 87% below the Chemicals median (#1257 of 1588)
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sudarshan Pharma Industries Ltd operates in the pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. The Company has a presence domestically and internationally, participating regularly in trade fairs and exhibitions. The Company exports mainly to South East Asia, the Middle East, and North Africa. The Company also supplies generic pharmaceutical formulation as 'Make to order' for bulk supply to hospitals and related healthcare organisations. The company has one reportable segment of Specialty Chemicals.
74GF Score
Get the complete analysis for BOM:543828
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543828 has been successfully added to your 
